# United Therapeutics Corporation (UTHR) · Edgar & Edgarette company card

> United Therapeutics (UTHR) grew revenue 10.6% in FY2025 to $3.2 billion, operating margin 46.9% against a -3.8% median for pharmaceutical preparations, equity 90.1% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1082554 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/UTHR) · [JSON](https://www.pops4.com/boards/company/UTHR.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $3.2B |
| Revenue growth, 1 year | 10.6% |
| Revenue growth per year | 17.2% |
| Operating margin | 46.9% (prior year 47.9%) |
| Net margin | 41.9% |
| Operating cash flow | $1.6B |
| Capital spending | $521M |
| Free cash flow | $1.0B |
| Cash | $1.6B |
| Long-term debt | — |
| Total assets | $7.9B |
| Total equity | $7.1B |
| Equity ÷ assets | 90.1% |
| Return on equity | 18.8% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: 16.93 (safe zone)
- Piotroski F: 8 of 9 (strong)
- Beneish M: -2.26 (below the −1.78 line)
- Health Harbor boat: New ship · no warning signs
- Cash Compass: Cash cow later · growing fast, and already turning revenue into cash

## Edgarette's reading

Exposure: revenue $3.2B (FY2025). Experience: revenue up 10.6% on the year, up 17.2% a year over 4 years; operating margin 46.9%, down from 47.9%. Soundness: equity 90.1% of assets, return on equity 18.8%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $3.2B and $3.9B next year (method v4.1: its own 4-year record of growth weighed at 50% against $1B–10B filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $3.0B to $4.2B. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin 46.9% against a -3.8% median; growth 10.6% against 13.7%.

Range logged 2026-09-25, receipt a06fbf154cfd7554, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 3, latest 2026-07-23 ([filing](https://www.sec.gov/Archives/edgar/data/1082554/000110465926086068/0001104659-26-086068-index.htm))

## Recent filings

- 8-K · filed 2026-11-04 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1082554/000108255426000036/0001082554-26-000036-index.htm)
- 10-Q · filed 2026-11-04 · [filing](https://www.sec.gov/Archives/edgar/data/1082554/000108255426000035/0001082554-26-000035-index.htm)
- 8-K · filed 2026-10-22 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1082554/000110465926117964/0001104659-26-117964-index.htm)
- 8-K · filed 2026-10-14 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1082554/000110465926115723/0001104659-26-115723-index.htm)
- 8-K · filed 2026-09-08 · 1.01 Entry into a Material Definitive Agreement; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1082554/000110465926105953/0001104659-26-105953-index.htm)
- 8-K · filed 2026-08-05 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1082554/000108255426000028/0001082554-26-000028-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001082554.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1082554

## Cite

POPS4, Edgar & Edgarette: United Therapeutics Corporation (UTHR) company card, from the company's own SEC filings, accessed 2026-11-05, https://www.pops4.com/boards/company/UTHR. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.